Innovative R&D

Innovative R&D

Innovative R&D
Recombinant Keratin
R&D platform
Leading-edge View
Industrial Advantages and Application Prospects of Recombinant Keratin in the Hair Care Sector

Aug,13,2026

Industrial Advantages and Application Prospects of Recombinant Keratin in the Hair Care Sector

Hair is a key component of beauty care, yet conventional hair‑care products often deliver limited results. Commercially available keratins are typically derived from wool or poultry feathers and do not fully match the sequence of human hair keratin, which restricts their efficacy. K31 is a type I acidic keratin and the principal protein in the human hair keratin complex, playing a critical role in maintaining hair’s tensile strength. In this study, the K31 gene (46 kDa) was expressed in Escherichia coli, with the recombinant protein accounting for approximately 35% of total cellular protein. Following refolding and purification by anion‑exchange FPLC, circular dichroism analysis confirmed proper folding, and MALDI‑TOF mass spectrometry verified that the product exhibited the expected characteristics of human K31. When applied to chemically damaged hair, recombinant K31 increased hair diameter by up to 49%, nearly doubled the mechanical strength of bleached strands after a single treatment, and efficiently straightened curly hair with a one‑hour application. K31 markedly improved the smoothness, diameter, and mechanical strength of damaged hair, providing robust scientific evidence for the industrial application of recombinant keratins in hair‑care formulations.

Read More

04th

Aug,2026

New Starting Point, New Journey | Hemos Bioscience R&D Center Officially Moves into the Chongqing Biomanufacturing Industry Pilot-Scale Platform

New Starting Point, New Journey | Hemos Bioscience R&D Center Officially Moves into the Chongqing Biomanufacturing Industry Pilot-Scale Platform

On August 1, Hemos’ Bioscience R&D Center officially moved into the Chongqing Biomanufacturing Industry Pilot-Scale Platform, marking a critical leap in its R&D capabilities—from laboratory-scale trials to pilot-scale production. Leveraging the platform’s resources, the company will accelerate technology validation and the commercialization of research outcomes, bridging the gap between the “lab” and the “production line.” The R&D team will adapt to this new environment, focus on breakthroughs in core technologies, and collaborate across departments to bring projects to fruition, injecting fresh momentum into the high-quality development of the biomanufacturing sector.

Read More

27th

Jul,2026

New Regulation Interpretation | With the new regulations on cosmetic ingredients now in effect, Recombinant Keratin is entering a golden period of accelerated industrialization.

New Regulation Interpretation | With the new regulations on cosmetic ingredients now in effect, Recombinant Keratin is entering a golden period of accelerated industrialization.

On July 15, the new regulations on cosmetic raw materials officially came into effect, shifting oversight from “strict entry, lenient management” to “risk-based classification.” This analysis explores how Recombinant Keratin is leveraging policy benefits—such as lower filing thresholds and clearer submission pathways—to enter a golden period of accelerated industrialization, as well as Hemos Bio’s core technological advantages in this field.

Read More

17th

Jul,2026

The Hair‑Care Benefits and Application Scenarios of Recombinant Keratin: An Interpretation of Research on Bioactive Design Peptides for Enhancing Hair Keratin

The Hair‑Care Benefits and Application Scenarios of Recombinant Keratin: An Interpretation of Research on Bioactive Design Peptides for Enhancing Hair Keratin

Hair keratin is a core protein that maintains the structure and function of hair; environmental and chemical stressors can readily lead to its degradation, resulting in dryness, breakage, and damage to the cuticle. In this study, leveraging computer‑aided design, we rationally screened and identified the tripeptide KCV (Tripeptide‑132), which was subsequently subjected to palmitoylation. Multi‑dimensional experiments were conducted to validate its ability to strengthen hair keratin. The results demonstrate that KCV and its derivatives efficiently bind to keratin, deeply penetrate the hair fiber, and significantly enhance tensile strength and resistance to breakage. By stabilizing keratin’s structure primarily through hydrogen‑bond‑driven noncovalent interactions, these compounds offer a precise and highly effective bioactive solution for repairing damaged hair. Drawing on these findings, we further elaborate on the technical advantages of recombinant keratin—such as structural homology, all‑round repair, and long‑lasting efficacy—providing valuable technical guidance and raw‑material selection strategies for hair‑care brands seeking to develop premium reparative products.

Read More

14th

Jul,2026

A delegation from Chongqing Yufu Holding Group and Chongqing Machinery & Electrical Group paid a visit to Hemos Bioscience for inspection and exchange.

A delegation from Chongqing Yufu Holding Group and Chongqing Machinery & Electrical Group paid a visit to Hemos Bioscience for inspection and exchange.

On July 10, Yufu Holdings and CQME Group inspected Hemos Bioscience, reviewing its recombinant keratin tech advances and industrialization progress. They discussed a "capita–industry–tech" partnership to deepen biomaterials cooperation and boost Chongqing's biopharma cluster.

Read More

24th

Jun,2026

Hemos has joined Chongqing’s biomanufacturing pilot platform, accelerating the industrialization of Recombinant Keratin across the board.

Hemos has joined Chongqing’s biomanufacturing pilot platform, accelerating the industrialization of Recombinant Keratin across the board.

Hemos Bioscience has officially joined Phase I of the Chongqing Biomanufacturing Pilot Platform as a first-core enterprise. Co-established by Bishan District and East China University of Science and Technology with a total investment of RMB 625 million, the platform features a 1L-to-30-ton fermentation system, filling the specialized pilot-scale gap in Southwest China. Leveraging its full-chain scale-up capabilities, Hemos will accelerate process finalization and scaled production of recombinant human keratin, bridging the lab-to-production pathway and supporting the development of Chongqing's 100-billion-yuan biopharmaceutical cluster.

Read More

< 1234 > proceed page
%E7%AC%AC%E4%B8%80%EF%BC%8C%E6%9C%80%EF%BC%8C%E4%BC%98%E7%A7%80%EF%BC%8C%E5%A2%9E%E5%BC%BA%EF%BC%8C%E4%B8%80%E6%B5%81%EF%BC%8C%E5%8D%93%E8%B6%8A%EF%BC%8C%E9%A2%86%E5%85%88%EF%BC%8C%E5%85%88%E8%BF%9B%EF%BC%8C%E5%BC%95%E9%A2%86%EF%BC%8C%E6%96%B0%E5%8A%A8%E6%80%81%2F%2F%2F%E6%96%B0%E9%97%BB%E9%80%9F%E9%80%92%EF%BC%8C%E9%A2%86%E5%86%9B%E8%80%85%EF%BC%8C%E9%A6%96%EF%BC%8C%E9%A1%B6%E5%B0%96

Sorry，当前栏目暂无内容!

您可以查看其他栏目或返回 首页

Sorry，The current column has no content!

You can view other columns or return Home